INAUGURAL MEETING OF BIOLOGICAL WARFARE AD HOC

File: 120396_sep96_decls92_0003.txt
Page: 0003
Total Pages: 8

Subject: INAUGURAL MEETING OF BIOLOGICAL WARFARE AD HOC                  

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003203

Folder Title: AAR INAUGURAL MEETING OF BIOLOGICAL WARFARE AD HOC COMMITTEE                                    

Document Number:          1

Folder SEQ  #:        176



                                    !CriftnrT   UNCLASSIFIED
                                    s) L

          e.       Discussion on Botulinum

                  (1) (U) Incubation period from 3 to 36 hours.
          Initial symptoms include generalized weakness, lassitude
          dizziness; neurological symptoms usually are present inii
          or early in disease; relatively easy to diagnosis clinici
          however, routine laboratory findings are of no value in
          diagnosis.
                  (2)       Pre- and post exposure prophylaxis and
          treatment was discussed. A pentavalent toxoid (A, B, C,
          given as a pre-exposure vaccine has been produced (under
          only limited quantities currently available.    It may be
          possible to increase production; however, large scale
          production may take up to six months. Limited data suggi
          that limited and transient antitoxin levels are induced i      3
          injections. The immune response to 1 or 2 doses of vacc:
          being researched.   A human pentavalent antitoxin given
          pre-exposure has been produced and is available in very        d
          quantities (under IND). Two other products given
          post-exposure, ecluine trivalent (A, B, E,) commercially
          produced by Connaught, and a equine heptavalent antitoxin
          B, C, D, E, F, and G) (no IND) are also available. The
          heptavalent antitoxin is the only product available in ti
          treatment of the "F" toxin which AFMIC reported that Irat
          possessed.

                 (3) (U) Supply of available vaccine (see 7B).

                 (4) (U) Immunization schedule. The currently
          recommended 5 dose schedule is at 0, 14, 84, and 365 daye

          7. @    RECOMMENDATIONS:
          I
          regarding the use of pentavalent toxoid at the present ti

              b. @    Proceed with procurement of an additional
          doses of Anthrax vaccine to supplement the


in 1-2 months and an additiona
          However, as the same company produces both the Anthrax va
          and the pentavalent toxoid, there may be some problems wi
          both items being manufactured simultaneously at these lev
          This issue is being researched.

              c. (U) Establish a permanent "Task Force on Biologic
          Warfare Issues."



                                A Pak ft@go9p
                                *)EljlftEl   UNCLASSIFIED

Document 8 f:/Week-36/BX003203/AAR INAUGURAL MEETING OF BIOLOGICAL WARFARE AD HOC COMMITTEE/inaugural meeting of biological warfare ad hoc:11259610134232
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = AAR INAUGURAL MEETING OF BIOLOGICAL WARFARE AD HOC COMMITTEE
Folder Seq # = 176
Subject = INAUGURAL MEETING OF BIOLOGICAL WARFARE AD HOC
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 25-NOV-1996